Immunotherapy in older patients with cancer

Hayflick, 1961, The serial cultivation of human diploid cell strains, Exp Cell Res, 25, 585, 10.1016/0014-4827(61)90192-6 von Zglinicki, 2005, Telomeres as biomarkers for ageing and age-related diseases, Curr Mol Med, 5, 197, 10.2174/1566524053586545 Bekaert, 2005, Telomere attrition as ageing biomarker, Anticancer Res, 25, 3011 Thakkar, 2014, Age-specific cancer incidence rates increase through the oldest age groups, Am J Med Sci, 348, 65, 10.1097/MAJ.0000000000000281 Pawelec, 2019, Does patient age influence anti-cancer immunity?, Semin Immunopathol, 41, 125, 10.1007/s00281-018-0697-6 Lynch, 2009, Thymic involution and immune reconstitution, Trends Immunol, 30, 366, 10.1016/j.it.2009.04.003 Lee, 2019, Causes and mechanisms of hematopoietic stem cell aging, Int J Mol Sci, 20, 1272, 10.3390/ijms20061272 Verschoor, 2013, Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer, J Leukoc Biol, 93, 633, 10.1189/jlb.0912461 Xia, 2016, An update on inflamm-aging: mechanisms, prevention, and treatment, J Immunol Res, 2016, 8426874, 10.1155/2016/8426874 Fulop, 2014, On the immunological theory of aging, Interdiscip Top Gerontol, 39, 163, 10.1159/000358904 Franceschi, 2000, Inflamm-aging. An evolutionary perspective on immunosenescence, Ann N Y Acad Sci, 908, 244, 10.1111/j.1749-6632.2000.tb06651.x Metcalf, 2017, Human monocyte subsets are transcriptionally and functionally altered in aging in response to pattern recognition receptor agonists, J Immunol, 199, 1405, 10.4049/jimmunol.1700148 Panda, 2010, Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response, J Immunol, 184, 2518, 10.4049/jimmunol.0901022 Agrawal, 2011, Impact of aging on dendritic cell functions in humans, Ageing Res Rev, 10, 336, 10.1016/j.arr.2010.06.004 Lindau, 2019, Cytomegalovirus exposure in the elderly does not reduce CD8 T cell repertoire diversity, J Immunol, 202, 476, 10.4049/jimmunol.1800217 Henson, 2014, p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8(+) T cells, J Clin Invest, 124, 4004, 10.1172/JCI75051 Fali, 2019, New insights into lymphocyte differentiation and aging from telomere length and telomerase activity measurements, J Immunol, 202, 1962, 10.4049/jimmunol.1801475 Lanna, 2017, A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging, Nat Immunol, 18, 354, 10.1038/ni.3665 Bjorkstrom, 2012, CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells, Blood, 120, 3455, 10.1182/blood-2012-03-416867 Voehringer, 2002, Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1), Blood, 100, 3698, 10.1182/blood-2002-02-0657 Seidel, 2018, Skin resident memory CD8(+) T cells are phenotypically and functionally distinct from circulating populations and lack immediate cytotoxic function, Clin Exp Immunol, 194, 79, 10.1111/cei.13189 Hashimoto, 2019, Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians, Proc Natl Acad Sci U S A, 116, 24242, 10.1073/pnas.1907883116 Briceno, 2016, Reduced naive CD8(+) T-cell priming efficacy in elderly adults, Aging Cell, 15, 14, 10.1111/acel.12384 Hailemichael, 2013, Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion, Nat Med, 19, 465, 10.1038/nm.3105 Apetoh, 2015, Consensus nomenclature for CD8(+) T cell phenotypes in cancer, OncoImmunology, 4, 10.1080/2162402X.2014.998538 Laurent, 2015, Interrelations of immunological parameters, nutrition, and healthcare-associated infections: prospective study in elderly in-patients, Clin Nutr, 34, 79, 10.1016/j.clnu.2014.01.012 Leng, 2010, Impact of aging on viral infections, Microb Infect, 12, 1120, 10.1016/j.micinf.2010.08.009 Jiang, 2009, Limited expansion of virus-specific CD8 T cells in the aged environment, Mech Ageing Dev, 130, 713, 10.1016/j.mad.2009.08.007 Sasaki, 2011, Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies, J Clin Invest, 121, 3109, 10.1172/JCI57834 Belongia, 2016, Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies, Lancet Infect Dis, 16, 942, 10.1016/S1473-3099(16)00129-8 Najarro, 2015, Telomere length as an indicator of the robustness of B- and T-cell response to influenza in older adults, J Infect Dis, 212, 1261, 10.1093/infdis/jiv202 Levin, 2003, Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine, J Infect Dis, 188, 1336, 10.1086/379048 Patel, 2018, Impact of zostavax vaccination on T-cell accumulation and cutaneous gene expression in the skin of older humans after varicella zoster virus antigen-specific challenge, J Infect Dis, 218, S88, 10.1093/infdis/jiy420 Schmader, 2012, Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years, Clin Infect Dis, 54, 922, 10.1093/cid/cir970 Willer, 2019, Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials, Vaccine, 37, 6262, 10.1016/j.vaccine.2019.09.028 Xu, 2020, Association between leucocyte telomere length and cardiovascular disease in a large general population in the United States, Sci Rep, 10, 80, 10.1038/s41598-019-57050-1 Haycock, 2014, Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis, BMJ, 349, g4227, 10.1136/bmj.g4227 Zgibor, 2017, Community-based healthy aging interventions for older adults with arthritis and multimorbidity, J Community Health, 42, 390, 10.1007/s10900-016-0268-5 Dilas, 2011, [Autoimmune thyroid disease and other non-endocrine autoimmune diseases], Med Pregl, 64, 183, 10.2298/MPNS1104183T Lindstrom, 2010, Rheumatoid arthritis: a role for immunosenescence?, J Am Geriatr Soc, 58, 1565, 10.1111/j.1532-5415.2010.02965.x Jagger, 2014, Regulatory T cells and the immune aging process: a mini-review, Gerontology, 60, 130, 10.1159/000355303 Onyema, 2015, Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study, BMC Canc, 15, 1016, 10.1186/s12885-015-2013-3 Kamphorst, 2017, Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent, Science, 355, 1423, 10.1126/science.aaf0683 Sagiv, 2016, NKG2D ligands mediate immunosurveillance of senescent cells, Aging, 8, 328, 10.18632/aging.100897 Pereira, 2019, Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition, Nat Commun, 10, 2387, 10.1038/s41467-019-10335-5 Tartour, 1994, Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma, Cancer Res, 54, 6243 Tartour, 1994, Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients, Br J Cancer, 69, 911, 10.1038/bjc.1994.175 Hui, 2017, T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, 355, 1428, 10.1126/science.aaf1292 Baitsch, 2011, Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients, J Clin Invest, 121, 2350, 10.1172/JCI46102 FDA. Hematology/oncology (cancer) approvals & safety notifications. https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications/; 2020. [accessed 10 February 2020]. Xin Yu, 2020, Trends in clinical development for PD-1/PD-L1 inhibitors, Nat Rev Drug Discov, 19, 163, 10.1038/d41573-019-00182-w Granier, 2017, Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer, ESMO Open, 2, 10.1136/esmoopen-2017-000213 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Garon, 2019, Five-year overall survival for patients with advanced NonSmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study, J Clin Oncol, 37, 2518, 10.1200/JCO.19.00934 De Guillebon, 2020, Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination, Int J Cancer, 147, 1509, 10.1002/ijc.32889 Granier, 2017, Tim-3 expression on tumor-Infiltrating PD-1(+)CD8(+) T cells correlates with poor clinical outcome in renal cell carcinoma, Cancer Res, 77, 1075, 10.1158/0008-5472.CAN-16-0274 Nizard, 2017, Induction of resident memory T cells enhances the efficacy of cancer vaccine, Nat Commun, 8, 15221, 10.1038/ncomms15221 Kennedy, 2020, A review of cancer immunotherapy toxicity, CA Cancer J Clin, 70, 86, 10.3322/caac.21596 Urwyler, 2020, Mechanisms of checkpoint inhibition induced adverse events, Clin Exp Immunol, 200, 141, 10.1111/cei.13421 Canoui-Poitrine, 2019, Inclusion of older patients with cancer in clinical trials: the SAGE prospective multicenter cohort survey, Oncologist, 24, e1351, 10.1634/theoncologist.2019-0166 Hamaker, 2012, The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer, Oncologist, 17, 1439, 10.1634/theoncologist.2012-0186 Wildiers, 2014, International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 32, 2595, 10.1200/JCO.2013.54.8347 Pamoukdjian, 2019, How to optimize cancer treatment in older patients: an overview of available geriatric tools, Am J Clin Oncol, 42, 109, 10.1097/COC.0000000000000488 Nishijima, 2016, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis, Cancer Treat Rev, 45, 30, 10.1016/j.ctrv.2016.02.006 Daste, 2017, Immune checkpoint inhibitors and elderly people: a review, Eur J Cancer, 82, 155, 10.1016/j.ejca.2017.05.044 Elias, 2018, Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis, J Immunother Cancer, 6, 26, 10.1186/s40425-018-0336-8 Ferrara, 2017, Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?, Cancer Treat Rev, 60, 60, 10.1016/j.ctrv.2017.08.003 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Herin, 2018, Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours, Eur J Cancer, 95, 68, 10.1016/j.ejca.2018.03.002 Elkrief, 2020, Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: real-world data from multicentric cohorts in Canada and France, J Geriatr Oncol, 11, 802, 10.1016/j.jgo.2020.01.002 Landre T, Taleb C, Nicolas P, Des Guetz G. Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour. J Clin Oncol 2016;34:3070. Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252 Gettinger, 2016, Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer, J Clin Oncol, 34, 2980, 10.1200/JCO.2016.66.9929 Spigel, 2019, Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 Years or older or with poor performance status (CheckMate 153), J Thorac Oncol, 14, 1628, 10.1016/j.jtho.2019.05.010 Grossi, 2018, Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme, Eur J Cancer, 100, 126, 10.1016/j.ejca.2018.05.015 Betof, 2017, Impact of age on outcomes with immunotherapy for patients with melanoma, Oncol, 22, 963, 10.1634/theoncologist.2016-0450 Rai, 2016, Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma, Ann Oncol, 27, vi379, 10.1093/annonc/mdw379.08 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Chiarion Sileni, 2014, Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J Exp Clin Cancer Res, 33, 30, 10.1186/1756-9966-33-30 Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Johnpulle, 2016, Responses to immune checkpoint inhibitors in nonagenarians, OncoImmunology, 5, 10.1080/2162402X.2016.1234572 Kugel, 2018, Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations, Clin Cancer Res, 24, 5347, 10.1158/1078-0432.CCR-18-1116 Ibrahim, 2018, Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol Immunother, 67, 1571, 10.1007/s00262-018-2219-8 Pasquini, 2019, Post-marketing use Outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US), Blood, 134, 764, 10.1182/blood-2019-124750 Bouchlaka, 2013, Impact of aging in cancer immunotherapy: the importance of using accurate preclinical models, OncoImmunology, 2, 10.4161/onci.27186 Friedman, 2016, Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+), J Clin Oncol, 34, 10009, 10.1200/JCO.2016.34.15_suppl.10009 Spigel, 2017, Is nivolumab safe and effective in elderly and PS3 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153, J Thorac Oncol, 12, S1287, 10.1016/j.jtho.2016.11.1821 Elias, 2017, Immunotherapy comes of age: immune aging & checkpoint inhibitors, J Geriatr Oncol, 8, 229, 10.1016/j.jgo.2017.02.001 Friedmann, 2016, Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). in ASCO, J Clin Oncol, 34, 10009, 10.1200/JCO.2016.34.15_suppl.10009 Champiat, 2017, Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1, Clin Cancer Res, 23, 1920, 10.1158/1078-0432.CCR-16-1741 Ratner, 2018, Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy, N Engl J Med, 378, 1947, 10.1056/NEJMc1803181 van Holstein, 2019, Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer, Drugs Aging, 36, 927, 10.1007/s40266-019-00697-2 Duggal, 2019, Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity?, Nat Rev Immunol, 19, 563, 10.1038/s41577-019-0177-9 Babu, 2019, Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy, Front Immunol, 10, 1965, 10.3389/fimmu.2019.01965 Corral de la Fuente, 2019, Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP), Ann Oncol, 30, II61, 10.1093/annonc/mdz063.067